Skip to main content
Top
Published in: Clinical Drug Investigation 10/2015

Open Access 01-10-2015 | Original Research Article

Assessment of Alcohol-Induced Dose Dumping with a Hydrocodone Bitartrate Extended-Release Tablet Formulated with CIMA® Abuse Deterrence Technology

Authors: Mona Darwish, Mary Bond, Ronghua Yang, William Tracewell, Philmore Robertson Jr

Published in: Clinical Drug Investigation | Issue 10/2015

Login to get access

Abstract

Background

Greater drug content requirements for extended-release (ER) opioids necessitate greater protection against dose dumping. Hydrocodone ER employs the CIMA® Abuse-Deterrence Technology platform, which provides resistance against rapid release of the active moiety when the tablet is manipulated or taken with alcohol.

Objective

Assess effects of alcohol on hydrocodone ER pharmacokinetics.

Study Design

Open-label, crossover (January 25–April 30, 2010).

Setting

Single center.

Participants

Forty healthy adults.

Intervention

Subjects received all four treatments in a randomized manner (separated by a minimum 5-day washout): hydrocodone ER 15 mg with 240 mL water and 240 mL orange juice containing 4, 20, and 40 % alcohol in a fasted state. Naltrexone was administered to minimize opioid-related adverse events.

Main Outcome Measure

Effect of alcohol on pharmacokinetics of hydrocodone ER assessed by comparing systemic exposure [maximum plasma drug concentration (C max) and area under the plasma drug concentration-versus-time curve from time 0 to infinity (AUC0–∞)] after administration with alcohol or with water.

Results

Geometric means ratios of hydrocodone ER with 4, 20, and 40 % alcohol relative to water were 1.05, 1.09, and 1.14, respectively, for C max and 1.07, 1.13, and 1.17, respectively, for AUC0–∞. All 90 % confidence intervals for these geometric means ratios fell within the limits of 0.8 and 1.25. Increasing alcohol concentrations did not notably affect systemic exposure but were associated with increased adverse events.

Conclusions

Hydrocodone ER tablets were resistant to dose dumping when administered with alcohol in healthy subjects based on similar systemic exposures observed across all treatments.
Literature
1.
go back to reference Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–30.PubMedCentralCrossRefPubMed Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–30.PubMedCentralCrossRefPubMed
2.
go back to reference Chelminski PR, Ives TJ, Felix KM, et al. A primary care, multi-disciplinary disease management program for opioid-treated patients with chronic non-cancer pain and a high burden of psychiatric comorbidity. BMC Health Serv Res. 2005;5(1):3.PubMedCentralCrossRefPubMed Chelminski PR, Ives TJ, Felix KM, et al. A primary care, multi-disciplinary disease management program for opioid-treated patients with chronic non-cancer pain and a high burden of psychiatric comorbidity. BMC Health Serv Res. 2005;5(1):3.PubMedCentralCrossRefPubMed
3.
go back to reference Reid MC, Engles-Horton LL, Weber MB, et al. Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med. 2002;17(3):173–9.PubMedCentralCrossRefPubMed Reid MC, Engles-Horton LL, Weber MB, et al. Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med. 2002;17(3):173–9.PubMedCentralCrossRefPubMed
6.
go back to reference Walden M, Nicholls FA, Smith KJ, et al. The effect of ethanol on the release of opioids from oral prolonged-release preparations. Drug Dev Ind Pharm. 2007;33(10):1101–11.PubMedCentralCrossRefPubMed Walden M, Nicholls FA, Smith KJ, et al. The effect of ethanol on the release of opioids from oral prolonged-release preparations. Drug Dev Ind Pharm. 2007;33(10):1101–11.PubMedCentralCrossRefPubMed
7.
go back to reference Traynor MJ, Brown MB, Pannala A, et al. Influence of alcohol on the release of tramadol from 24-h controlled-release formulations during in vitro dissolution experiments. Drug Dev Ind Pharm. 2008;34(8):885–9.CrossRefPubMed Traynor MJ, Brown MB, Pannala A, et al. Influence of alcohol on the release of tramadol from 24-h controlled-release formulations during in vitro dissolution experiments. Drug Dev Ind Pharm. 2008;34(8):885–9.CrossRefPubMed
12.
go back to reference Oxycontin [package insert]. Stamford: Purdue Pharma L.P.; 2013. Oxycontin [package insert]. Stamford: Purdue Pharma L.P.; 2013.
13.
go back to reference Duragesic [package insert]. Titusville: Janssen Pharmaceutica Products, L.P.; 2011. Duragesic [package insert]. Titusville: Janssen Pharmaceutica Products, L.P.; 2011.
14.
go back to reference MS Contin [package insert]. Stamford: Purdue Pharma L.P.; 2009. MS Contin [package insert]. Stamford: Purdue Pharma L.P.; 2009.
15.
go back to reference OxyIR (oxycodone hydrochloride) immediate-release oral capsules [package insert]. Stamford: Purdue Pharma L.P.; 2010. OxyIR (oxycodone hydrochloride) immediate-release oral capsules [package insert]. Stamford: Purdue Pharma L.P.; 2010.
16.
go back to reference Opana ER [package insert]. Chadds Ford: Endo Pharmaceuticals Inc.; 2013. Opana ER [package insert]. Chadds Ford: Endo Pharmaceuticals Inc.; 2013.
17.
go back to reference Avinza [package insert]. Bristol: King Pharmaceuticals, Inc.; 2008. Avinza [package insert]. Bristol: King Pharmaceuticals, Inc.; 2008.
20.
go back to reference Johnson FK, Ciric S, Boudriau S, et al. Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. J Clin Pharmacol. 2012;52(2):747–56.CrossRefPubMed Johnson FK, Ciric S, Boudriau S, et al. Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. J Clin Pharmacol. 2012;52(2):747–56.CrossRefPubMed
Metadata
Title
Assessment of Alcohol-Induced Dose Dumping with a Hydrocodone Bitartrate Extended-Release Tablet Formulated with CIMA® Abuse Deterrence Technology
Authors
Mona Darwish
Mary Bond
Ronghua Yang
William Tracewell
Philmore Robertson Jr
Publication date
01-10-2015
Publisher
Springer International Publishing
Published in
Clinical Drug Investigation / Issue 10/2015
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.1007/s40261-015-0324-4

Other articles of this Issue 10/2015

Clinical Drug Investigation 10/2015 Go to the issue